areas of activity

our areas of interest are focused both on novel approaches to correct and potentiate mutant CFTR protein and to find anti-inflammatory drugs tailored on the specific pathophysiology of chronic lung disease of cystic fibrosis patients, a “cystic fibrosis – tailored anti-inflammatory therapy” still representing an unmet need in the field

identification and design of new molecules is the first but not the unique arm of our activity since we work in parallel on the “low-hanging fruit” approach aimed on the application of the drug repurposing strategy, in order to shorten the timing and reduce the costs of the application to patients

our main goal is to translate the best molecules discovered in really safe and effective drugs for patients, although we are well aware that good translational science is made possible only if we run basic science at the highest possible standards, to understand fine mechanisms and identify molecular targets for new drugs to cure cystic fibrosis lung disease

our projects

  • IGM, Insensitive CFTR Gating Mutations: new generation potentiators tailored to CFTR gating mutations insensitive to VX-770
  • PNAs, stabilizers and amplifiers of corrected mutant CFTR proteinepigenetics as a pharmacological approach for cystic fibrosis
  • TMA and the chemical family of furocoumarins: modelling an improved class of anti-inflammatory molecules
  • MCU and functional regulation of mitochondrianew molecular targets to tackle cystic fibrosis lung inflammation
  • BSS, when old drugs learn new tricks, betasitosterol from traditional medicine to anti-inflammatory molecular therapy: a safe pharmaceutical repurposing